TORRENT PHARMACEUTICALS Ltd - QUARTERLY RESULTS - Q2 FY 15 ( SPE 2014) - Net Sales up 29% Net Profit Up 75% YoY

TORRENT PHARMACEUTICALS LIMITED

SAMIR MEHTA,CHAIRMAN

QUARTERLY RESULTS

Q2 FY 15 ( SPE 2014)

TORRENT PHARAM has posted impressive results for Q2 FY 15.

Net Sales have increased 10% QoQ and 29% YoY.

Total expenses have increased steeply, more than proportionately by 27% QoQ and less than proportionately by 23% YoY.

Consequently, operating profit has decreased by 33% QoQ and increased by 38% YoY.

Profit Before Tax has also fallen by 33% QoQ and increased by 55% YoY.

Due to Lower Tax, Net Profit has fallen only by 23% QoQ and increased impressively by 75% YoY. Thus, the year on Year performance, which is more relevant has grown by 75%. 

As per the Press release, the business of Elder pharma acquired by the company has also recorded impressive growth during the first half of current year.

We can expect better and more impressive performances from Torrent Pharma in the future.

RESULTS TABLE

Torrent Pharma	Q2 FY 15	Q1 FY 15	Dif % QoQ	Q2 FY14	Dif% YoY
NET SALES	1203	1092	10.16	936	28.53
TOTAL INCOME	1217	1114	9.25	972	25.21
TOTAL EXPENSES	1000	790	26.58	815	22.7
OPT	217	324	-33.02	157	38.22
PBT	235	349	-32.66	152	54.61
TAX	37	93	-60.22	39	-5.13
NPT	198	256	-22.66	113	75.22
EQUITY(fv.rs.5)	85	85	0	85	0
EPS	11.69	15.12	-22.69	6.64	76.05

Corporate Profile ::

Torrent Pharma, the flagship company of Torrent Group, is ranked amongst the top pharma companies of India. It is a dominant player in the therapeutic areas of cardiovascular (CV) and central nervous system (CNS) and has achieved significant presence in gastro-intestinal, diabetology, anti-infective and pain management segments. 

Recently it has also forayed into the oncology therapeutic segment while also strengthening its focus on gynecology and pediatric segments.

It has three world-class manufacturing facilities at Indrad (Gujarat), Baddi (Himachal Pradesh) and Sikkim. The facilities are approved by USFDA, WHO, MHRA, TGA and other global regulatory bodies. A new facility is taking shape at Dahej SEZ in Western India, which will cater to the international markets.Torrent Pharma is the sole manufacturer of Insulin Formulations for Novo Nordisk in India since the early ‘90s and has also set up a dedicated formulation and packaging facility for Insulin. 

Its modern and well-equipped R&D Centre is ranked amongst the best in the country and has a team of highly qualified scientists working on various Drug Discovery and Development projects. The R&D Centre has been approved by USFDA and various other regulatory authorities. 

Recently, Torrent Pharma acquired the branded domestic formulations business of Elder Pharmaceuticals in India and Nepal. The acquisition comprises a portfolio of 30 brands including market-leading brands in the Women's Healthcare, Pain Management, Wound Care and Nutraceuticals therapeutic segments. The transaction also involves the transfer of employees engaged in sales, marketing and operations of the India Business.

Torrent Pharma has a strong international presence spanning over 70 countries across five continents with over 1200 product registrations. It has wholly owned subsidiaries in USA, UK, Germany, Brazil, Russia, Mexico, Philippines, Australia and other major markets. These wholly owned subsidiaries spearheads the company’s entry into several new regulated and semi regulated international markets.

 *  *  *  E  N  D  *  *  *